Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,778 public trials 699 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

NCT05962606

Conditions
Community-Acquired Infections, Community-Acquired Pneumonia, Hemic and Lymphatic Diseases, +14 more
Locations
  • University of Alabama at Birmingham Heersink School of Medicine Birmingham, Alabama, United States
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Clinique Saint Pierre Ottignies, Belgium
  • Centre Hospitalier Argenteuil Argenteuil, France
View all 27 locations
View Trial Details
Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

NCT02601313

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Banner MD Anderson Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • University California Los Angeles (UCLA) Santa Monica, California, United States
  • Stanford University Stanford, California, United States
View all 32 locations
View Trial Details
Completed

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

NCT04703686

Conditions
Diffuse Large B-cell Lymphoma Refractory, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • CHU Amiens Picardie Site sud Amiens, France
  • CHU de Clermont Ferrand Clermont-Ferrand, France
  • Hopital Henri Mondor Créteil, France
  • CHU de Dijon - Hôpital le Bocage Dijon, France
View all 19 locations
View Trial Details
Completed

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00006721

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Alaska Regional Hospital Cancer Center Anchorage, Alaska, United States
  • Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Hembree Mercy Cancer Center at St. Edward Mercy Medical Center Fort Smith, Arkansas, United States
  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 259 locations
View Trial Details
Completed

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

NCT02723994

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +16 more
Locations
  • The Childrens Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Children'S Hospital Phoenix, Arizona, United States
  • Arkansas Childrens Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Fontana, California, United States
View all 111 locations
View Trial Details
Completed

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

NCT03458260

Conditions
Aggressive Non-Hodgkin Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • AZ Sint Jan Bruges, Belgium
  • Institut Jules Bordet - Centre des tumeurs de l'ULB Brussels, Belgium
  • Centre Hospitalier de Jolimont Haine-Saint-Paul, Belgium
  • CH d'Avignon Avignon, France
View all 22 locations
View Trial Details
Completed

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

NCT03939026

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Stanford University Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Completed

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

NCT04282018

Conditions
Advanced Solid Tumor, Chronic Disease, Chronic Lymphocytic Leukemia, +27 more
Locations
  • Blacktown Cancer and Haematology Centre Blacktown, New South Wales, Australia
  • Saint Vincents Hospital Sydney Darlinghurst, New South Wales, Australia
  • Pindara Private Hospital Benowa, Queensland, Australia
  • Gallipoli Medical Research Foundation Greenslopes, Queensland, Australia
View all 24 locations
View Trial Details
Completed

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Stanford Cancer Center Stanford, California, United States
  • Stanford Hospital and Clinics, Investigational Drug Services Stanford, California, United States
View all 63 locations
View Trial Details

Related conditions